Seno Medical Instruments Announces Pilot Study Data of Imagio® Breast Imaging System at RSNA 2015 Annual Meeting

Seno Medical Instruments Announces Pilot Study Data of Imagio® Breast Imaging System at RSNA 2015 Annual Meeting

Press releases may be edited for formatting or style | December 21, 2015
SAN ANTONIO, Dec. 21, 2015 /PRNewswire/ -- Seno Medical Instruments, Inc., the company pioneering the development of an opto-acoustic (OA) device as a new tool to improve the process of diagnosing breast cancer, announced results of its Pilot Study portion of the PIONEER pivotal study. The pilot study demonstrated the potential of the company's Imagio breast imaging system to improve physicians' ability to accurately classify benign breast masses compared to traditional ultrasound methods. The results of the 100 subject pilot study, conducted as the initial part of a larger U.S.-based, multicenter PIONEER pivotal study of over 2,000 subjects, were presented at the annual meeting of the Radiological Society of North America (RSNA) on December 2 in Chicago, IL.

The PIONEER study is being conducted to demonstrate the ability of the Imagio OA breast imaging system to downgrade BI-RADS® (Breast Imaging-Reporting and Data System) scores. Specifically, whether masses originally scored BI-RADS (BR) 4a or 4b (in which a suspicious abnormality is discovered and a biopsy is recommended) could be downgraded to either BR 3 (probably benign, <2% likelihood of malignancy with short-interval follow-up recommended) or 2 (benign) and if masses coded BR 3 could be downgraded to 2.

Seven independent breast radiologist readers (IRs) and an expert radiologist (ER) trainer blindly assessed 102 masses from the pilot study cases using only Imagio OA images. Among these subjects, there were 75 biopsied masses (39 benign, 36 malignant). Gray-scale ultrasound images were taken with the Imagio system's conventional ultrasound immediately prior to the OA exam. These images were designated the internal ultrasound control (IUC). Later, the IRs assigned a BR score to these images.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Using OA, the IRs downgraded conventional diagnostic ultrasound findings classified BR 3 masses to BR 2 in 33% of cases, BR 4a masses to BR 2 or 3 in 53% of cases, and BR 4b masses to BR 3 or 2 in 33% of cases. Using OA, the IRs downgraded BI-RADS categories of the internal ultrasound control-classified BR 3 masses to BR 2 in 43% of cases, BR 4a to either BR 3 or 2 in 43% of cases and BR 4b masses to either BR 3 or 2 in 13% of cases. OA had 97.6% sensitivity and 44.4% specificity.

"Downgrading benign masses classified as BR 4b (moderate suspicion), 4a (low suspicion) and 3 without missing cancers is an unmet need that the Imagio OA breast imaging system can potentially help address," said Erin Neuschler, MD, Northwestern Medicine Radiologist, Assistant Professor of Radiology at the Northwestern University Feinberg School of Medicine and the Co-Principal Investigator of the PIONEER Study. "If these pilot findings are verified after the completion of the multicenter PIONEER Study, we will have confirmation that the Imagio OA breast imaging system could help women not only avoid biopsy procedures but also multiple short interval follow-up ultrasound exams over two years."

You Must Be Logged In To Post A Comment